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Abstract 
 
 
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent developmental disorder, 
associated with a range of long-term impairments. Variation in DNA methylation, an 
epigenetic mechanism, is implicated in both neurobiological functioning and psychiatric 
health. However, the potential role of DNA methylation in ADHD symptoms is currently 
unclear. In this study, we examined data from the Avon Longitudinal Study of Parents and 
Children (ALSPAC) – specifically the subsample forming the Accessible Resource for 
Integrated Epigenomics Studies (ARIES) – which includes (i) peripheral measures of DNA 
methylation (Illumina 450k) at birth (n=817, 49% male) and age 7 (n=892, 50% male) and 
(ii) trajectories of ADHD symptoms ( 7-15 yrs). We first employed a genome-wide analysis  
to test whether DNA methylation at birth associates with later ADHD trajectories; and then 
followed up at age 7 to investigate the stability of associations across early childhood. We 
found that DNA methylation at birth differentiated ADHD trajectories across multiple 
genomic locations, including probes annotated to SKI (involved in neural tube development), 
ZNF544 (previously implicated in ADHD), ST3GAL3 (linked to intellectual disability) and 
PEX2 (related to perixosomal processes). None of these probes maintained an  association 
with ADHD trajectories at age 7. Findings lend novel insights into the epigenetic landscape of 
ADHD symptoms, highlighting the potential importance of DNA methylation variation in 
genes related to neurodevelopmental and peroxisomal processes, which play a key role in the 
maturation and stability of cortical circuits. 
3  
Introduction 
 
 
Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most prevalent and 
disabling psychiatric conditions in childhood and adolescence,
1 
often persisting into 
adulthood
2 
and associating with a range of long-term impairments.
3–6 
Like other psychiatric 
disorders, the aetiology of ADHD is complex and multifactorial. While epidemiological 
studies have identified numerous environmental risk factors,
7,8 
family-based studies have also 
documented the importance of genetic factors in the development of ADHD 
symptomatology,
9–11 
although genome-wide association studies have yet to find genetic 
variants robustly associated with ADHD.
10,12,13 
The mechanisms underlying the association 
between these risk factors and the development of ADHD symptoms remain to be elucidated. 
In recent years, epigenetic processes, such as DNA methylation, regulating gene expression 
have emerged as candidate mechanisms as they have been associated with 
environmental/genetic risk as well as neurobiological functioning and psychiatric 
wellbeing.
14–17
 
 
Recent research has begun to demonstrate the potential of epigenetic research for 
understanding ADHD.
18,19 
However, current literature on the topic remains scant and presents 
a number of important limitations. First, the majority of existing studies have been based on 
candidate genes (e.g. dopaminergic genes), which precludes the identification of novel 
findings. A methylome-wide analysis, in contrast, is hypothesis-free with respect to which 
genes might be involved and hence has the potential to detect novel biological associations.
20 
Second, studies have relied primarily on cross-sectional designs featuring DNA methylation  
at a single time point. This has precluded the possibility of examining whether altered DNA 
methylation patterns are a risk factor for and/or consequence of ADHD, as well as  
establishing the stability of associations across time. 
4  
To our knowledge, only one study to date has conducted a methylome-wide analysis of 
ADHD, implicating several potential biological pathways related to inflammatory 
mechanisms, such as homocysteine and fatty acid oxidation.
21 
However, the study focussed 
on a relatively small sample (N = 105) of boys and relied in part on a priori information to 
identify differentially methylated sites. The cross-sectional design also meant that it was not 
possible to disentangle epigenetic predictors of ADHD from a posteriori markers of ADHD 
and/or associated characteristics (e.g. medication or stress resulting from ADHD symptoms). 
In the present study we aimed to address these gaps in the literature, by conducting the first 
methylome-wide study of ADHD symptomatology in a large population-based sample 
featuring repeated measures of DNA methylation and the use of a prospective design 
spanning birth to adolescence. 
 
 
 
 
 
Methods 
 
 
Participants 
 
 
Participants were drawn from the Accessible Resource for Integrated Epigenomics 
Studies (ARIES, www.ariesepigenomics.org.uk),
22  
containing DNA methylation data for a 
subset of 1018 mother-offspring pairs and nested within the Avon Longitudinal Study of 
Parents and Children (ALSPAC).  ALSPAC is an ongoing epidemiological study of children 
born from 14,541 pregnant women residing in Avon, UK, with an expected delivery date 
between April 1991 and December 1992 (85% of eligible population).
23 
Informed consent 
was obtained from all ALSPAC participants and ethical approval was obtained from the 
ALSPAC Law and Ethics Committee as well as Local Research Committees. The original 
ALSPAC sample is representative of the general population.
24 
Please note that the study 
5  
website contains details of all the data that is available through a fully searchable data 
dictionary:   http://www.bris.ac.uk/alspac/researchers/dataaccess/data-dictionary/. 
For this study, we included youth from ARIES who had available data on ADHD 
symptomatology ratings (age 7-15) as well as epigenetic data at birth (n = 817, 49% male) 
and/or age 7 (n = 892, 50% male). The overlap was n = 783 participants with DNA 
methylation at birth and age 7 as well as ADHD ratings (see Supplementary section 1.1 for 
details). 
 
 
 
Measures 
 
ADHD 
 
ADHD symptomatology was assessed via maternal ratings at ages 7, 10, 13 and 15 
years, using the well-validated Development and Well-Being Assessment interview 
(DAWBA).
25 
The DAWBA was administered via computer, generating the following 
‘probability bands’ (i.e. levels of prediction of the probability of disorder for a DSM-IV 
diagnosis of ADHD, ranging from 0 – very unlikely – to 5 – probable): 0: < 0.1% probability 
of children in this band having the disorder; 1: ~0.5%; 2: ~3%; 3: ~15%; 4: ~40%; 5: >70%, 
respectively. See Supplementary section 1.2 for more details. 
 
 
 
DNA methylation data 
 
500ng genomic DNA from blood (cord at birth; whole at age 7) was bisulfite- 
converted using the EZ-DNA methylation kit (Zymo Research, Orange, CA, USA). DNA 
methylation was quantified using the Illumina HumanMethylation450 BeadChip (HM450k; 
Illumina, USA) with arrays scanned using an Illumina iScan (software version 3.3.28). 
Samples (nbirth = 25; nage 7 = 8) or probes (nbirth = 7873; nage 7 = 4861) that failed quality 
control (>1% probes/samples with background detection p-value >= 0.05) were excluded 
6  
from further analysis. Sex checks were performed using X/Y chromosome methylation. 
Genotype probes on the HM450k were compared between samples from the same individual 
and against SNP-chip data to identify and remove any sample mismatches. Samples were 
quantile normalised using the dasen function within the wateRmelon package (version 1.4.0) 
in R. Normalization performance was evaluated using all three testing metrics in wateRmelon 
(genki assessing SNP-related probes, dmrse assessing imprinted probes and seabi, assessing 
gender differences).  Methylation levels were then indexed by beta values (corresponding to 
the ratio of methylated signal divided by the sum of the methylated and unmethylated signal). 
Probes known to be cross-reactive or polymorphic
26,27 
and SNP (i.e. “rs”) probes were 
 
removed (n = 72,068). We also removed participants with non-caucasian or missing   ethnicity 
(based on self-reports; n = 61), leaving a total of 828 (cord) and 903 samples (age 7) after 
quality control. Cell type proportions (CD8 T lymphocytes, CD4 T lymphocytes, natural killer 
cells, B lymphocytes, monocytes and granulocytes) for each participant were estimated 
using the reference-based approach detailed in Houseman et al.
28 
As a final step, we 
 
regressed out chip and cell type to remove potentially confounding effects. For more 
information, see Supplementary section 1.3. 
 
 
 
 
Analyses 
 
 
ADHD trajectories 
 
 
Trajectories of hyperactivity/inattention across 7 to 15 years were estimated using k- 
means for longitudinal data (Package KmL).
29–31 
This non-parametric procedure classifies 
participants into developmental trajectories, i.e. homogenous subgroups following similar 
developmental patterns. Each participant is first assigned arbitrarily to one initial trajectory. 
Next, the center (mean) of each trajectory is calculated and each participant 
7  
is reassigned to the closest trajectory. The operation is repeated until convergence (i.e. until 
no further mean adjustment change occurs in the trajectories). The process from assignment 
to convergence is then repeated (500 times in the present study) to make  sure that the 
solution is not dependent on the initial assignment. The best solution is determined by a 
criterion that maximizes a ratio computed by dividing the trace of the between-variance by 
the trace of the within-variance (i.e. maximizing the differences between trajectories and 
maximizing the homogeneity within trajectories). Additional details on the procedure and the 
choice of the best solution are provided in Supplementary sections 1.4 and 1.5. The final 
sample consisted of nbirth = 777 and nage7 = 
842 in the low trajectory group against nbirth = 40 and nage7 = 50 in the high trajectory 
 
group (see results section for further details). 
 
 
 
 
 
Methylome-wide analysis 
 
 
Methylome-wide association analysis between DNA methylation (407,462 probes, 
cell type and batch-corrected) and ADHD trajectories were performed at birth, adjusting for 
sex, using a general linear model. Differentially methylated probes (DMPs) surviving a False 
Discovery Rate (FDR) correction of q < 0.05 were visually inspected to assess equal 
variance between trajectories and analysed further to determine whether they were also 
nominally significant at age 7 (i.e. follow-forward approach, FDR-corrected q<0.05) and 
whether the direction of association was consistent across time points. All analyses were 
performed in R (version 3.0.2) using package IMA.
32 
 
 
 
Code availability 
 
Computer code used in our analyses is available from the authors upon request. 
8  
Network analysis 
 
To further analyse underlying genetic networks of ADHD trajectory-associated 
DMPs, we imported and analysed all genes related to FDR-corrected DMPs at birth using 
GeneMANIA (http://www.genemania.org) bioinformatics software with default parameters. 
For more information on GeneMANIA methods, see Supplementary section 2.2 and 
references.
33,34
 
 
 
 
 
 
 
 
Results 
 
 
Trajectory analyses of the DAWBA ADHD scores yielded a 3 trajectory solution 
(Figure 1 and Supplementary section 1.5). Participants in the high trajectory (6.1%) had 
DAWBA band scores of around 3 across time points. Conversely, participants in the null 
trajectory (67.4%) and in the low trajectory (26.5%), had stable scores of around 0 and 1 
respectively, corresponding to a close to zero probability of being ADHD cases. In the 
methylome-wide analyses, we therefore used a binary variable grouping the null and the low 
trajectories (called low thereafter) (nbirth = 777 and nage7 = 842) against the high trajectory 
(nbirth = 40 and nage7 = 50). 
 
 
 
 
Methylome-wide analysis of ADHD trajectories 
 
 
At birth, 13 probes were differentially methylated between ADHD trajectories after 
FDR correction (q < 0.05; Table 1 and Figure 2A). Inspection of the QQ-plot (Supplementary 
Figure 3) and a lambda statistic of 1.056 provided little evidence of inflation of test statistics. 
Additionally, visual inspection of boxplots gave no strong indication for a violation of equal 
variance assumption between trajectories for any of these 13 probes (see 
9  
Supplementary section 2.1). Cg24481594, the most significant DMP (βstdn = -0.198; p = 
1.51*10-8; q = 0.006), was hypo-methylated in the high trajectory and is annotated to SKI, a 
gene related to Transforming Growth Factor-beta (TGF-beta) signalling and neural tube 
development.
35,36 
Other DMPs of interest were located in genes such as (i) EPX 
(cg27469152; βstdn = -0.181; p = 2.26*10-7; q = 0.031; Figure 2B), a member of the 
peroxidase gene family, and PEX2 (cg16290904; βstdn = 0.173; p = 7.35*10-7; q = 0.048; 
Figure 2C), a peroxisomal membrane protein gene involved in myelin production and fatty-
acid metabolism; (ii) ST3GAL3 (cg09989037; βstdn = -0.172; p = 9.46*10-7; q = 
0.048), a gene linked to mental retardation;
37 
(iii) FBXW5 (cg13714586; βstdn = 0.170; p = 
 
1.30*10-6; q = 0.048), associated with interleukin-1B signalling; (iv) ELF3 (cg05653018; 
βstdn = 0.169; p = 1.43*10-6; q = 0.048), involved in preimplantation development; and (v) 
ZNF544 (cg26263766; βstdn = 0.173; p = 8.72*10-7; q = 0.048; Figure 2D), implicated in 
transcriptional regulation and previously shown to associate with ADHD.
38 
Absolute mean 
 
percent methylation difference between the high and low trajectory group for the 13 DMPs 
passing FDR-correction was 2.3% (range 0.6 – 4.8). 
 
 
 
 
 
Network analysis of FDR-corrected probes 
 
 
All genes annotated to FDR-corrected DMPs (n = 13) were entered into a network 
analysis using GeneMANIA, which is  based on known genetic and physical interactions, 
shared pathways and protein domains as well as protein co-expression data. The analysis 
showed that these genes form a compact cluster network (see Figure 3). The most enriched 
biological functions related to peroxisomal processes (involving the genes PEX2, PEX10 and 
PEX12; pFDR ranging from 0.008 - 0.012; Supplementary Table 3), followed by functions 
related to transcription activity (pFDR = 0.019). However, it should be noted that 
10  
only PEX2 was directly measured, while the involvement of PEX10 and PEX12 was indirectly 
inferred based on shared protein domains and physical interactions. 
 
 
 
 
 
Follow-forward analysis at age 7 
 
 
As a last step, we investigated whether any of the 13 DMPs that differentiated ADHD 
trajectories at birth also did so at age 7. While two of the 13 DMPs at birth also showed 
nominally significant effects at age 7 (cg27469152 located in the gene EPX; βstdn = -  0.090; p 
= 0.008; and cg16290904 located in the gene PEX2; βstdn = -0.077;p = 0.022; Table 1), no 
probe remained significant after FDR-correction for 13 test. The direction   of effect was 
consistent for cg27469152 (decreased methylation in the high trajectory group, both at birth 
and at age 7), but not for cg16290904. 
 
 
 
 
 
Additional analyses 
 
 
Given that a minority (see Supplementary Figure 1) of participants had DNA 
methylation data only at birth or age 7, we repeated the analyses in a subsample with 
complete DNA methylation data at both time points (n = 783). In agreement with our 
previous findings, effect sizes at birth were consistent in direction and size. Mean percent 
variation compared to the original effect sizes was 5.5% (standard error ± 2.6). Similar to the 
main analysis, no marker replicated at a FDR-corrected significance level at age 7 years 
(Supplementary section 2.3). 
11  
Discussion 
 
 
In this study, we employed a methylome-wide prospective analysis (birth, age 7) with 
trajectories of ADHD symptoms (7-15 years). We identified 13 probes at birth that were 
differentially methylated between high and low trajectories of ADHD symptoms, none of 
which continued to be differentially methylated at age 7. Detected probes were located in the 
vicinity of genes implicated in peroxisomal processes, neural tube development and mental 
retardation, as well as one gene previously associated with ADHD. We first discuss our 
findings in light of the few previous epigenetic studies on ADHD, before turning to potentially 
relevant biological mechanisms suggested by our findings. We also discuss differences in 
results between birth and age 7 years from a developmental perspective. 
 
Our findings both contrast and support previous epigenetic studies of ADHD. With 
regard to contrasting results, we found no evidence of differential methylation in VIPR2 (a 
gene linked to mood disorders and circadian rhythm regulation), which was identified as a 
top hit by the only other published methylome-wide study on ADHD.
21 
We also found no 
evidence of differential methylation in DRD4, which was reported as significantly associated 
with ADHD in two previous candidate gene studies.
18,19 
A number of factors may explain 
these discrepancies, including differences in: (i) samples (population versus clinical); (ii) 
assessment (diagnosis versus continuous ratings); (iii) analytical methods (candidate genes 
vs. methylome-wide); (iv) design (prospective/longitudinal vs cross-sectional); and (v) 
developmental period examined (birth vs childhood). As a result, consideration of these 
differences should be applied when interpreting the findings of the present study. 
 
Conversely, our findings regarding peroxisomal processes lend support to the 
involvement of mechanisms related to fatty acid oxidation in ADHD, as previously 
12  
reported by Wilmot et al.
21 
Peroxisomes are cell components that play a key role in the 
metabolism of essential fatty acids from the omega-3 family. In particular, dietary alpha- 
linolenic acids are transformed into docosahexaenoic acid (DHA) through a final β-oxidation 
reaction that takes place in the peroxisomes.
40 
DHA is particularly relevant as it accumulates 
in brain tissue at a rapid rate during the third trimester of pregnancy and continues to do so 
throughout early childhood and adolescence, playing an essential role in the maturation and 
stability of cortical circuits as well as in several other processes (e.g. implication in 
neurotransmitter systems including dopamine and serotonin).
42 
 
 
Deficits in DHA have been related to several psychiatric disorders, including ADHD.
42,43 
For 
instance,   a recent meta-analysis of case control studies has demonstrated that ADHD is 
associated with robust blood DHA deficits.
44  
Furthermore, meta-analyses of randomized 
controlled trials in ADHD patients have shown a small but statistically significant effect of 
omega-3  fatty acid supplementation on ADHD symptoms
43 
as well as some effects on 
cognition in people with low dietary omega-3 intake.
45 
 Consequently, our findings, together 
with those of previous research,
21 
suggest that  early life methylation patterns in the 
peroxisomal network contribute to ADHD symptomatology in childhood and adolescence, 
possibly through disruptive effects on DHA synthesis. If the association between DNA 
methylation patterns in this network and ADHD is indeed mediated by peroxisome 
abnormalities leading to DHA deficits, the 
13  
future studies should investigate whether dietary intake of preformed DHA, which 
bypasses peroxisome biosynthesis, mitigates the effect of altered DNA methylation 
patterns. 
 
In addition to peroxisomal processes, significant probes pointed towards several other 
processes associated with the development of the central nervous system. In particular, the 
most significant probe at birth was linked to SKI proto-oncogene, which functions as a 
suppressor of transforming growth factor-beta signalling, and is implicated in neural tube 
development and myelination.
35,36,46 
A study by Atanasoski et al.
46 
showed that 
overexpression of Ski in cultured Schwann cells – the main glial cells in the peripheral 
nervous system - causes upregulation of myelin protein genes, indicating that Ski is an 
essential regulator that controls Schwann cell myelination. Interestingly, children with 
neurofibromatosis type 1 – a genetic disorder that can result in neurofibromas, which 
primarily affect Schwann cells
47 – are three times as likely to meet DSM-IV diagnostic 
 
criteria for ADHD compared to their unaffected siblings.
48 
An additional probe, which we 
identified, was linked to ST3GAL3, a gene encoding a membrane protein involved in cellular 
communication located on chr1p34.1. This region (and ST3GAL3 itself) had  been previously 
associated with intellectual disability using linkage analysis,  chromosome sorting and next-
generation sequencing.
37,49,50  
Furthermore, we identified two probes that are linked to 
ZNF544 and ZNF454, respectively. Both genes belong to the same zinc finger family (C2H2-
type) and are involved in gene transcription. Strikingly, ZNF544 - along with several other 
ZNF genes - was previously flagged up in GWAS analysis of ADHD.
38 
Using data from 376 
family trios and a composite quantitative phenotype of ADHD symptoms based on DSM-IV 
criteria, the authors of that study identified, among others, a SNP linked to ZNF544. This 
marker is around 
14  
30,000 basepairs away from the CpG site identified in this study, which is associated with the 
same gene. 
 
Among the 13 probes identified at birth, none were still associated at age 7 years with 
ADHD trajectories after FDR-correction. A number of non-exclusive factors may drive this 
non-replication. First, a number of the 13 probes detected at birth may have been false 
positives. Although we had a much larger sample than any previous study, false positives are 
still possible. Second, early life methylation patterns may be particularly important for the 
development of ADHD. For example, one probe was linked to a gene involved in 
preimplantation development whose differential methylation may be only detectable at birth. 
In addition, it has been shown that DHA accrual in the brain is particularly important in the 
third trimester of pregnancy and the first year of life.
42 
These and other processes that are 
 
more salient during early development may lead to enduring individual differences (e.g. in 
brain structure) without the epigenetic association being maintained. Third, there is mounting 
evidence that DNA methylation patterns change considerably across development.
51,52 
Consequently, a large proportion of epigenetic effects may be specific to certain 
developmental epochs. In the present case, differences in methylation patterns between birth 
and age 7 may reflect differences in environmental exposures at both ages and/or 
developmental genetic influences that have been reported for ADHD symptoms.
11 
Importantly, given the current lack of similar prospective epigenetic studies in ADHD, it is 
not yet clear what should be expected in terms of continuity vs. discontinuity in epigenetic 
patterns. Therefore, the above considerations remain inevitably speculative and necessitate 
further investigation. 
15  
Limitations 
 
 
The present findings should be interpreted in light of a number of limitations. Because of the 
use of a population-based sample, the proportion of youth showing severe ADHD 
symptomatology across time was relatively small and necessitates replication using larger 
clinical samples. Furthermore, although the DAWBA is a well-validated and extensively used 
measure based on DSM-IV criteria, it is not, per se, a clinical diagnostic tool. As such, it will 
be important in future to replicate findings in clinical populations were diagnostic assessments 
are available. As psychostimulants can influence DNA 
methylation,
53 
the use of clinical samples would also facilitate analyses investigating the 
 
effect of psychostimulant treatment on DNA methylation, which we were unable to do in the 
present sample. The use of a larger number of cases vs controls will also make it   possible to 
examine potential sex differences in the association between DNA methylation  and ADHD 
symptoms. 
 
Findings were based on DNA methylation from blood samples. Given that methylation 
patterns can be tissue-specific, the extent to which these changes reflect changes in the brain 
will need to be established. This is particularly relevant given that markers identified were 
related to genes involved in neural function and development. The analysis of transcriptomic 
data will also be important for assessing the functional significance of DNA methylation 
changes to gene expression levels. 
 
The markers identified in this study were not validated using alternative methods such as 
bisulfite-pyrosequencing. While we note that our previous work with bisulfite- 
pyrosequencing has demonstrated that the Illumina HM450 is a robust and sensitive platform 
for the detection of DNA methylation differences,
54,55 
future work is needed to validate our 
findings further. 
16  
 
 
 
Conclusion 
 
 
In conclusion, the present findings suggest that epigenetic mechanisms related to specific 
neurodevelopmental processes, such as neural tube development and peroxisomal 
mechanisms, are implicated in ADHD symptomatology. These results lend novel insights 
into longitudinal epigenetic risk markers for ADHD, pinpointing specific targets for further 
interrogation. 
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Tables and Figures 
 
 
 
 
 
 
Figure 1. Trajectory analyses of the DAWBA ADHD scores yielded a 3 trajectory solution. 
Trajectories were estimated using k-means for longitudinal data, a non-parametric 
procedure, which classifies participants into homogenous subgroups following similar 
developmental patterns (trajectories). See method and results section as well as 
Supplementary sections 1.4 and 1.5 for statistical details. 
 
 
 
 
 
Figure 2. Manhattan plot and bar graphs of methylome-wide results at birth. A) CpG 
chromosome positions are plotted against -log10 p-values. The red line indicates FDR- 
corrected significance threshold. Results were derived using a general linear model between 
DNA methylation (407,462 probes at birth, cell type and batch-corrected) and ADHD 
trajectories, adjusting for sex. See method section for further statistical details. B-D) Bar 
graphs (mean ± s.e.m.) of three DMPs associated with ADHD trajectories. 
 
 
 
 
 
Figure 3. Gene network analysis using GeneMANIA. Darker circles represent genes 
associated with the 13 probes found to be related to ADHD trajectories in the methylome- 
wide analysis at birth. Lighted circles represent additional genes predicted by GeneMANIA 
based on genetic and physical interactions, shared pathways and protein domains as well as 
protein co-expression data. The gene network analysis demonstrates that, rather than being 
isolated (e.g. FBXW5), these genes clustered into a complex interconnected network. For 
more information on GeneMANIA methods, see Supplementary section 2.2. 
  
 
 
Table 1. FDR-corrected probes that associate with ADHD trajectory. Estimates given for birth and age 7, ranked by birth p-values. Chr, chromosome; 
StdB, standardized regression beta (negative values indicate hypomethylation in the high trajectory group); p, uncorrected p-value; q, FDR-corrected 
value; s.d., standard deviation. 
 
 
CpG Gene Chr Position   Birth     Age 7  
 
 
 
 
StdB 
 
 
 
 
p 
 
 
 
 
q 
 
 
mean±s.d. low 
trajectory 
group 
 
 
 
mean±s.d. high 
trajectory group 
 
 
 
 
StdB 
 
 
 
 
p 
 
 
 
 
q 
 
mean±s.d. 
low 
trajectory 
group 
 
mean±s.d. 
high 
trajectory 
group 
 
cg24481594 SKI 1 2190850 -0.198 1.51E-08 0.006 0.828 (0.026) 0.805 (0.034) 0.005 0.876 0.963 0.777 (0.025) 0.777 (0.024) 
cg03905179 MAFK 7 1582588 -0.182 2.00E-07 0.031 0.761 (0.040) 0.727 (0.076) -0.002 0.951 0.963 0.753 (0.034) 0.752 (0.028) 
cg27469152 EPX 17 56282313 -0.181 2.26E-07 0.031 0.793 (0.024) 0.771 (0.032) -0.090 0.008 0.104 0.772 (0.032) 0.758 (0.030) 
cg15096815 JUN 1 59249838 -0.178 3.53E-07 0.036 0.105 (0.010) 0.097 (0.009) 0.002 0.963 0.963 0.104 (0.010) 0.104 (0.010) 
cg01324543 CCDC30 1 42999439 -0.174 7.21E-07 0.048 0.871 (0.025) 0.851 (0.036) 0.023 0.497 0.881 0.876 (0.020) 0.877 (0.022) 
cg16290904 PEX2 8 77912348 0.173 7.35E-07 0.048 0.055 (0.006) 0.061 (0.017) -0.077 0.022 0.143 0.061 (0.011) 0.058 (0.013) 
cg26263766 ZNF544 19 58739734 0.173 8.72E-07 0.048 0.064 (0.019) 0.079 (0.032) 0.012 0.729 0.948 0.063 (0.020) 0.064 (0.025) 
cg09989037 ST3GAL3 1 44300942 -0.172 9.46E-07 0.048 0.443 (0.055) 0.402 (0.069) -0.056 0.099 0.322 0.463 (0.044) 0.454 (0.048) 
cg18587973 CDADC1 13 49822535 0.170 1.20E-06 0.048 0.076 (0.034) 0.108 (0.092) -0.015 0.656 0.948 0.086 (0.029) 0.085 (0.039) 
cg22193912 MAFG 17 79881523 0.169 1.28E-06 0.048 0.171 (0.056) 0.218 (0.082) -0.041 0.224 0.570 0.311 (0.053) 0.303 (0.063) 
cg13714586 FBXW5 9 139838358 0.170 1.30E-06 0.048 0.049 (0.005) 0.055 (0.026) -0.038 0.263 0.570 0.050 (0.007) 0.049 (0.005) 
cg05653018 ELF3 1 201979533 0.169 1.43E-06 0.048 0.799 (0.045) 0.833 (0.035) 0.059 0.082 0.322 0.841 (0.027) 0.847 (0.021) 
   cg24843380    ZNF454 5 178367827 0.168 1.56E-06 0.049 0.075 (0.010) 0.087 (0.053) 0.021 0.542    0.881    0.093 (0.021)    0.096 (0.015)   
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